Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

NCT02612311 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

603

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic/Business decision

Conditions

Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: Obinutuzumab
BIOLOGICAL: Ublituximab
DRUG: TGR-1202
DRUG: Chlorambucil

Sponsor

TG Therapeutics, Inc.